News item
TGA confirms decision to not register lecanemab (LEQEMBI)
Following a request from the sponsor to reconsider their decision, the TGA has confirmed the initial decision to not register the medicine on the basis that the safety and efficacy of the medicine were not satisfactorily established.
This is for Doceo members
Membership is free. Join in a minute, or log in if you’re already a member.